Navigation Links
The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly
Date:6/24/2013

CHICAGO, June 24, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Walgreens (NYSE: WAG-Free Report), Express Scripts Holding Company (Nasdaq: ESRX-Free Report), Haemonetics Corporation (NYSE: HAE-Free Report), ResMed Inc. (NYSE: RMD-Free Report) and Eli Lilly and Company (NYSE: LLY-Free Report).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)  

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday's Analyst Blog:

Will Walgreens Miss 3Q Earnings?

 

Walgreens (NYSE: WAG-Free Report) is set to report third-quarter fiscal 2013 results before the opening bell on Tuesday, Jun 25. In the second quarter, this drug retail giant posted a 1.05% positive earnings surprise after two consecutive misses. Let's see how things are shaping up prior to the announcement.

Factors to Consider this Quarter

As reported earlier, Walgreens' total sales came in at $18.34 in the third quarter of fiscal 2013. Despite sales growth of 3.3% year over year, the quarterly sales trailed the Zacks Consensus Estimate for the fifth time in a row.

Nonetheless, the company witnessed higher comparable store sales and front-end comparable store sales. Additionally, comparable pharmacy sales improved in the third quarter.

As it crossed the halfway mark of fiscal 2013, things started looking up for Walgreens. Following the reconciliation withExpress Scripts Holding Company (Nasdaq: ESRX-Free Report), Walgreens is sanguine about increasing returns of customers. This is reflected in the higher number of prescriptions filled at the company's comparable stores in the third quarter.

Walgreens' timely progress to deliver first-year synergy targets following its Alliance Boots deal in encouraging. Notably, the company's third-quarter numbers will reflect whether its deal-making spree is paying off.

However, the generic wave in the pharmaceutical industry continues to hurt revenues. The company also faces tough industry conditions and competitive headwinds.

Earnings Whispers?

Our proven model does not conclusively show that Walgreens will likely beat earnings estimates this quarter. That is because a stock needs to have both a positive Earnings ESP (Read: Zacks Earnings ESP: A Better Method) as well as a Zacks Rank of #1, 2 or 3 for this to happen. This is not the case here as you will see below.

Zacks Earnings ESP: The Most Accurate Estimate stands at $0.90 while the Zacks Consensus Estimate is also at $0.90. This comes to a difference of 0.00%.

Zacks Rank #3 (Hold): Walgreens carries a Zacks Rank #3 (Hold), which increases the predictive power of ESP. However, the Zacks Rank #3 when combined with a 0.00% ESP makes surprise prediction difficult.

Other Stocks to Consider

Here are some other companies you may want to consider as our model shows that these have the right combination of ingredients to post an earnings beat this quarter:  

Haemonetics Corporation (NYSE: HAE-Free Report), Earnings ESP of +2.13% and a Zacks Rank #1 (Strong Buy)

ResMed Inc. (NYSE: RMD-Free Report), Earnings ESP of +4.84% and a Zacks Rank #3 (Hold)

 

Label Updates for Lilly Drugs

Eli Lilly and Company (NYSE: LLY-Free Report) and Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that the labels for their diabetes drugs, Tradjenta (linagliptin) and Jentadueto (linagliptin plus metformin) will be updated in the US. Eli Lilly and Boehringer Ingelheim said that the label updates had been approved by the US Food and Drug Administration (FDA).

The label updates will provide information needed to ensure the proper use of these medicines by physicians, pharmacists and patients.

Eli Lilly and Boehringer Ingelheim said that the Prescribing Information (PI) section of the labels for Tradjenta and Jentadueto will carry additional information regarding the risk of pancreatitis. The Important Limitations of Use sections within the Indications and Usage sections will be updated with the information that both drugs have not been studied in patients with a history of pancreatitis.

Moreover, this section will state that it is not known whether patients with a history of pancreatitis will be at a higher risk for the development of pancreatitis while using Tradjenta or Jentadueto.

Meanwhile, the Warnings and Precautions section will include information regarding post marketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking linagliptin.

The Patient Counseling Information section will also include information about the potential risk and symptoms of pancreatitis. This section of the label carries instructions asking healthcare providers to inform their patients about the potential risks and benefits associated with the use of Tradjenta or Jentadueto.

Eli Lilly and Boehringer Ingelheim also said that they will inform physicians prescribing dipeptidyl peptidase 4 (DPP-4) inhibitors and pharmacists about the label update.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

 

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

 

Get the full Report on WAG - FREE

Get the full Report on ESRX - FREE

Get the full Report on HAE - FREE

Get the full Report on RMD - FREE

Get the full Report on LLY - FREE

 

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

 

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

 


'/>"/>
SOURCE Zacks Investment Research, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy
2. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
3. The Zacks Analyst Blog Highlights: Exxon Mobil, Statoil, Chevron, Braskem and Cubist Pharmaceuticals
4. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
5. Zacks Investment Ideas feature highlights: PharMerica, First Defiance Financial, American Railcar Industries and Big 5 Sporting Goods
6. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
7. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
8. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
9. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
10. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 SI-BONE, Inc., a medical ... iFuse Implant System, a minimally invasive surgical (MIS) ... the sacroiliac (SI) joint, announced the publication of ... MIS SI joint fusion for patients suffering from ... or SI joint disruption.  In the first article, ...
(Date:2/11/2016)... CITY, Calif. , Feb. 11, 2016  AcelRx ... a podium presentation will be made at the 38th ... and Wound Care Symposium, which is being held ... This international conference covers the latest advancements in wound ... by the American Burn Association, Australian-New Zealand Burns Association, ...
(Date:2/11/2016)... , Feb. 11, 2016  NanoViricides, Inc. ... it has entered into an agreement with the ... nanoviricides® drug candidates in standard animal models of ... , Research Director. Dr. Romanowski has extensive experience ... --> Eric Romanowski , Research ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... LaserShip, a regional parcel carrier that services the eastern U.S., ... last Friday in order to aid in the Flint water crisis. In 2014, LaserShip ... located in Clio, only 15 miles away from Flint. , “We have deep roots ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting ... Healthcare, recently partnered with Heart City Health Center to improve access ... years, Heart City Health Center has provided the Elkhart community with access to ...
(Date:2/10/2016)... ... , ... 10 Best Water is excited to announce a new ... that topped the list as a result of their commitment to offering clients creative, ... Tibet 5100, a top notch water company that specializes in providing the public with ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... measure change in their patients. Research shows that the Goal Attainment Scale (GAS) ... therapists overcome this challenge and learn more about the Goal Attainment Scale, Education ...
Breaking Medicine News(10 mins):